Galvus (vildagliptin) - DPP-IV Inhibitor / Oral Antidiabetic Agent
Key Data:
Drug (Brand / Generic)
Galvus (vildagliptin)
Company / Licensee
Novartis
Therapy Class
DPP-IV inhibitor
Product Description
Inhibits action of DPP-IV, so delaying degradation of GLP-1
Current Indication
Type 2 diabetes
Market Sector
Diabetes
Development Status
Approved Europe; pre-registration US
